Cancer Immunology Reserch

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0263. Online ahead of print. ABSTRACT Cytotoxic chemotherapy that kills cancer cells can also elicit anti-tumor immune responses. Therefore, understanding the immunogenic context of cytotoxic chemotherapy can improve combination immunotherapies. In this study, we sought to improve our understanding about dendritic cell (DC) dynamics in cytotoxic chemotherapy-treated tumor … Read more

Cancer Immunol Res. 2025 Mar 4;13(3):309. doi: 10.1158/2326-6066.CIR-13-3-WWR. NO ABSTRACT PMID:40033981 | DOI:10.1158/2326-6066.CIR-13-3-WWR

Cancer Immunol Res. 2025 Feb 26. doi: 10.1158/2326-6066.CIR-24-1094. Online ahead of print. ABSTRACT Denosumab, a RANKL inhibitor, is primarily used to prevent osteoclastogenesis in the treatment of conditions such as osteoporosis, bone metastasis, and giant cell tumour of bone (GCTB). RANKL also plays an important role in immunity by activating NF-κB and its target genes, … Read more

Cancer Immunol Res. 2025 Feb 25:OF1-OF7. doi: 10.1158/2326-6066.CIR-24-1046. Online ahead of print. ABSTRACT The advent of syngeneic mouse tumor models provided the scientific foundation for cancer immunotherapies now in widespread use. However, in many respects, these models do not faithfully recapitulate the interactions between cancer cells and the immune systems of human patients who have … Read more

Cancer Immunol Res. 2025 Feb 21. doi: 10.1158/2326-6066.CIR-24-0591. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for many cancers but have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment (TME) and is associated with poor response to ICIs. The primary source … Read more

Cancer Immunol Res. 2025 Feb 12. doi: 10.1158/2326-6066.CIR-24-0335. Online ahead of print. ABSTRACT Traditional anti-cancer therapies induce tumor cell death and subsequent release of Damage Associated Molecular Patterns (DAMPs) that activate the innate inflammatory response. Paradoxically, after treatment, macrophages often adopt a pro-wound healing, rather than pro-inflammatory, phenotype and contribute to cancer progression. We found … Read more

Cancer Immunol Res. 2025 Feb 11. doi: 10.1158/2326-6066.CIR-24-0513. Online ahead of print. ABSTRACT Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such … Read more

Cancer Immunol Res. 2025 Feb 7. doi: 10.1158/2326-6066.CIR-24-0103. Online ahead of print. ABSTRACT The tumor microenvironment (TME) in solid tumors contains myeloid cells that modulate local immune activity. STING signaling activation in these myeloid cells enhances local type I interferon (IFN) production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid … Read more

Cancer Immunol Res. 2025 Feb 3;13(2):161. doi: 10.1158/2326-6066.CIR-13-2-WWR. NO ABSTRACT PMID:39895312 | DOI:10.1158/2326-6066.CIR-13-2-WWR

Cancer Immunol Res. 2025 Jan 31. doi: 10.1158/2326-6066.CIR-24-0979. Online ahead of print. ABSTRACT Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy, and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis … Read more